Source: TRIANGLE BUSINESS JOURNAL, 3/26/20


As the world continues the search for potential treatments and vaccines to stem the COVID-19 pandemic, Duke University Hospital has announced some of its patients will be enrolled into a national trial for a leading treatment option. Duke's campus hospital will join the first national study for remdesivir – a antiviral agent that was previously tested in humans with the Ebola virus disease. The drug has, according to Duke, "shown promise in animal studies against MERS and SARS" – diseases that emerge from different strains of coronavirus than the one currently causing the global pandemic. 

For more of this story, click here.